A new slow-release form of the drug risperidone ― an antipsychotic given to people with schizophrenia, autism and other psychiatric conditions ― lasts in the blood days instead of hours, according to research presented today at the Society for Neuroscience meeting.

In the past two weeks, autism researchers and advocacy groups have been agog with news that autism could be linked to an extremely rare group of metabolic diseases.